- Email: [email protected]
Dyadic International reports 2010 financial results
FOCUS The new unit is ideally located to serve the customers for HPC in South America.
ON
C ATA LY S T S
requirement of the ethanol producers of the future.
Chemical Engineering World, Dec 2010, 45 (12), 115 (Website: http://www.cewindia.com)
Danisco Results 3Q 2010-2011, 17 Mar 2011, 13-14 (Danisco A/S, Langebrogade 1, PO Box 17, DK-1001 Copenhagen K, Denmark. Tel: +45 3266 2000. Fax: +45 3266 2175. Website: http://www.danisco.com)
Clariant AGM approves capital increase for takeover of more than 95% of SüdChemie shares
DSM and Codexis sign enzyme supply agreement
At the Annual General Meeting of Clariant AG, held on 31 Mar 2011, the way was cleared for takeover of more than 95% of the shares in Süd-Chemie AG. Clariant’s shareholders voted in favour of a capital increase, which is a basic requirement for takeover of the Süd-Chemie shares by Clariant. Part of the transaction is to be realised in the form of a share swap with SüdChemie’s long-standing share-holders. Press release from: Süd-Chemie AG, Lenbachplatz 6, 80333 Munich, Germany. Tel: +49 89 5110 0. Fax: +49 89 5110 375. Website: http://www.sud-chemie.com (31 Mar 2011)
Danisco announcement of results for 3Q 2010-2011: Genencor For its 3Q 2010 (period ends 31 Jan 2011), the Genencor segment of Danisco A/S has reported revenue of DKR 1306 M (DKR 1142 M for its 3Q 2009), EBITDA of DKR 265 M (DKR 191 M), and EBIT of DKR 201 M (DKR 128 M). For the first nine months of its fiscal 2010, this segment has reported revenue of DKR 3868 M (DKR 3320 M for the same period of its 2009), EBITDA of DKR 860 M (DKR 631 M), and EBIT of DKR 671 M (DKR 447 M). All major product areas contributed to organic growth. Sales of enzymes for grain processing, including bioethanol production, continued at a high level. Enzymes for both food and animal nutrition solutions progressed well, thus continuing to leverage the synergies between the company’s business areas of food and enzymes and the divisions’ shared technology access – and the acquisition of Agtech (microbial-based products for the animal nutrition industry) continued to progress well. DuPont Danisco Cellulosic Ethanol LLC (DDCE), the company’s partnership with DuPont on second-generation bioethanol, continued to work towards integrated solutions that will not only ensure more efficient enzyme use and lower unit costs but also strive towards reducing the overall CAPEX
MAY 2011
DSM has obtained the rights to use Codexis’ custom biocatalysts and services, and has secured the supply of Codexis enzymes for the commercialization of sustainable enzyme-based pharmaceutical production based on its own InnoSyn route scouting services. Codexis’ technology allows the development of cost-efficient and eco-friendly production processes for active pharmaceutical ingredients and intermediates, says DSM. DSM’s InnoSyn route scouting services combine enzyme technology with synthetic methods. Manufacturing Chemist, Feb 2011, 82 (2), 16 (Website: http://www.manufacturingchemist.com/)
Dyadic International reports 2010 financial results Dyadic International Inc announced financial results for year ended Dec 2010. Total revenue for 2010 decreased to approximately $8.4 M (approximately $21.4 M for 2009). Net product related revenue for 2010 increased 9% to approximately $7.4 M (approximately $6.8 M for 2009). Licence fee revenue decreased to approximately $37,250 for 2010 as ($10.3 M for 2009). R&D revenue decreased to approximately $1 M for 2010 (approximately $4.3 M for 2009). Net loss for 2010 was approximately $5.5 M, or $0.18/basic and fully diluted share (net income of approximately $5.2 M, or $0.17/basic and $0.16/fully diluted share for 2009). R&D expenses were $1,240,510 during 2010 ($1,211,035 in 2009). Dyadic International Inc financial results 2010, 10 Mar 2011 (Dyadic International Inc, 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477 5094, USA. Tel: +1 561 743 8333. Fax: +1 561 743 8343. Website: http://www.dyadic-group.com)
Hyperion signs nanotube deal with Bayer USA-based Hyperion Catalysis International Inc and Bayer
MaterialSciences AG have entered into a licence agreement that will allow Bayer to market its Baytubes carbon nanotubes for application within a specified area under Hyperion’s patent portfolio. Hyperion’s Fibril carbon nanotubes are used to confer electrical conductivity. Plastics News, 16 Mar 2011 (Website: http://www.plasticsnews.com) & Chemical Week, 21 Mar 2011, 173 (7), 4
Novozymes targets fuel ethanol Novozymes aims to generate a turnover of ca DKR 6 bn (around €800 M) in the biotechnology segment by 2018. The company plans to expand the business with biofertilizers and microorganisms during the next few years. Novozymes recently acquired EMD Crop Science Division from German pharmaceuticals and chemicals group Merck KGaA in Darmstadt for around €222 M. Novozyme generates a turnover of ca €82 M/y and EMD Crop Bioscience of around €45 M/y. EMD Crop Bioscience achieves an average growth rate of 15%/y. Novozymes is the world’s largest manufacturer of industrial enzymes with a market share of around 47%. The company predicts that the US biofuels industry will grow by 5% in 2011 and will produce around 52 M litres of ethanol. Around 19% of Novozymes sales target the ethanol industry. At the beginning of 2010 the company launched a new enzyme (Ctec2) for the manufacture of cellulose bioethanol and expects that the total cost of such a production will decrease to €0.55-0.60 per litre. Chemische Rundschau, Mar 2011, (3), 4-7 (Website: http://www.chemische-rundschau.ch/) (in German)
Novozymes reorganises reporting of enzyme sales Novozymes reported sales of enzymes for the bioenergy sector of DKR 1846 M for 2010 which was in line with the forecast of Jyske Bank. Enzymes for ethanol production comprise a substantial and growing part of operations. They did belong to the technical enzymes business area but this has now been dismantled, so that around DKR 3 bn in turnover has been reallocated to other business areas. Around 60% of the 2010 turnover of DKR 3065 M for technical
3
ON
C ATA LY S T S
requirement of the ethanol producers of the future.
Chemical Engineering World, Dec 2010, 45 (12), 115 (Website: http://www.cewindia.com)
Danisco Results 3Q 2010-2011, 17 Mar 2011, 13-14 (Danisco A/S, Langebrogade 1, PO Box 17, DK-1001 Copenhagen K, Denmark. Tel: +45 3266 2000. Fax: +45 3266 2175. Website: http://www.danisco.com)
Clariant AGM approves capital increase for takeover of more than 95% of SüdChemie shares
DSM and Codexis sign enzyme supply agreement
At the Annual General Meeting of Clariant AG, held on 31 Mar 2011, the way was cleared for takeover of more than 95% of the shares in Süd-Chemie AG. Clariant’s shareholders voted in favour of a capital increase, which is a basic requirement for takeover of the Süd-Chemie shares by Clariant. Part of the transaction is to be realised in the form of a share swap with SüdChemie’s long-standing share-holders. Press release from: Süd-Chemie AG, Lenbachplatz 6, 80333 Munich, Germany. Tel: +49 89 5110 0. Fax: +49 89 5110 375. Website: http://www.sud-chemie.com (31 Mar 2011)
Danisco announcement of results for 3Q 2010-2011: Genencor For its 3Q 2010 (period ends 31 Jan 2011), the Genencor segment of Danisco A/S has reported revenue of DKR 1306 M (DKR 1142 M for its 3Q 2009), EBITDA of DKR 265 M (DKR 191 M), and EBIT of DKR 201 M (DKR 128 M). For the first nine months of its fiscal 2010, this segment has reported revenue of DKR 3868 M (DKR 3320 M for the same period of its 2009), EBITDA of DKR 860 M (DKR 631 M), and EBIT of DKR 671 M (DKR 447 M). All major product areas contributed to organic growth. Sales of enzymes for grain processing, including bioethanol production, continued at a high level. Enzymes for both food and animal nutrition solutions progressed well, thus continuing to leverage the synergies between the company’s business areas of food and enzymes and the divisions’ shared technology access – and the acquisition of Agtech (microbial-based products for the animal nutrition industry) continued to progress well. DuPont Danisco Cellulosic Ethanol LLC (DDCE), the company’s partnership with DuPont on second-generation bioethanol, continued to work towards integrated solutions that will not only ensure more efficient enzyme use and lower unit costs but also strive towards reducing the overall CAPEX
MAY 2011
DSM has obtained the rights to use Codexis’ custom biocatalysts and services, and has secured the supply of Codexis enzymes for the commercialization of sustainable enzyme-based pharmaceutical production based on its own InnoSyn route scouting services. Codexis’ technology allows the development of cost-efficient and eco-friendly production processes for active pharmaceutical ingredients and intermediates, says DSM. DSM’s InnoSyn route scouting services combine enzyme technology with synthetic methods. Manufacturing Chemist, Feb 2011, 82 (2), 16 (Website: http://www.manufacturingchemist.com/)
Dyadic International reports 2010 financial results Dyadic International Inc announced financial results for year ended Dec 2010. Total revenue for 2010 decreased to approximately $8.4 M (approximately $21.4 M for 2009). Net product related revenue for 2010 increased 9% to approximately $7.4 M (approximately $6.8 M for 2009). Licence fee revenue decreased to approximately $37,250 for 2010 as ($10.3 M for 2009). R&D revenue decreased to approximately $1 M for 2010 (approximately $4.3 M for 2009). Net loss for 2010 was approximately $5.5 M, or $0.18/basic and fully diluted share (net income of approximately $5.2 M, or $0.17/basic and $0.16/fully diluted share for 2009). R&D expenses were $1,240,510 during 2010 ($1,211,035 in 2009). Dyadic International Inc financial results 2010, 10 Mar 2011 (Dyadic International Inc, 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477 5094, USA. Tel: +1 561 743 8333. Fax: +1 561 743 8343. Website: http://www.dyadic-group.com)
Hyperion signs nanotube deal with Bayer USA-based Hyperion Catalysis International Inc and Bayer
MaterialSciences AG have entered into a licence agreement that will allow Bayer to market its Baytubes carbon nanotubes for application within a specified area under Hyperion’s patent portfolio. Hyperion’s Fibril carbon nanotubes are used to confer electrical conductivity. Plastics News, 16 Mar 2011 (Website: http://www.plasticsnews.com) & Chemical Week, 21 Mar 2011, 173 (7), 4
Novozymes targets fuel ethanol Novozymes aims to generate a turnover of ca DKR 6 bn (around €800 M) in the biotechnology segment by 2018. The company plans to expand the business with biofertilizers and microorganisms during the next few years. Novozymes recently acquired EMD Crop Science Division from German pharmaceuticals and chemicals group Merck KGaA in Darmstadt for around €222 M. Novozyme generates a turnover of ca €82 M/y and EMD Crop Bioscience of around €45 M/y. EMD Crop Bioscience achieves an average growth rate of 15%/y. Novozymes is the world’s largest manufacturer of industrial enzymes with a market share of around 47%. The company predicts that the US biofuels industry will grow by 5% in 2011 and will produce around 52 M litres of ethanol. Around 19% of Novozymes sales target the ethanol industry. At the beginning of 2010 the company launched a new enzyme (Ctec2) for the manufacture of cellulose bioethanol and expects that the total cost of such a production will decrease to €0.55-0.60 per litre. Chemische Rundschau, Mar 2011, (3), 4-7 (Website: http://www.chemische-rundschau.ch/) (in German)
Novozymes reorganises reporting of enzyme sales Novozymes reported sales of enzymes for the bioenergy sector of DKR 1846 M for 2010 which was in line with the forecast of Jyske Bank. Enzymes for ethanol production comprise a substantial and growing part of operations. They did belong to the technical enzymes business area but this has now been dismantled, so that around DKR 3 bn in turnover has been reallocated to other business areas. Around 60% of the 2010 turnover of DKR 3065 M for technical
3